RecruitingPHASE1, PHASE2NCT05481879

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

Studying Steinert myotonic dystrophy

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Dyne Therapeutics
Intervention: DYNE-101(drug)
Enrollment: 116 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2022 – 2029

Study locations (17)

Indiana University School of Medicine, Indianapolis, Indiana, United States
University of Iowa, Iowa City, Iowa, United States
University of Rochester Medical Center, Rochester, New York, United States
Neurology Rare Disease Center, Denton, Texas, United States
Virginia Commonwealth University (VCU), Richmond, Virginia, United States
St. Vincent's Hospital, Fitzroy, Victoria, Australia
CHU de Nantes, Nantes, France
Institut de Myologie, Paris, France
Charité - Universitätsmedizin Berlin, Berlin, Germany
Ludwig Maximilians University, Munich - Friedrich Baur Institut, Munich, Germany
Centro Clinico Nemo, Milan, Italy
Fondazione Policlinico Universitario A Gemelli-Rome, Rome, Italy
Radboud Medical Center, Nijmegen, Netherlands
NZCR Auckland, Auckland, New Zealand
University College London Hospitals, London, United Kingdom
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05481879 on ClinicalTrials.gov

Other trials for Steinert myotonic dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Steinert myotonic dystrophy →

← Back to all trials